Wellington Management Group LLP Purchases 161,986 Shares of Guardant Health, Inc. (NASDAQ:GH)

Wellington Management Group LLP lifted its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 24.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 834,084 shares of the company’s stock after purchasing an additional 161,986 shares during the quarter. Wellington Management Group LLP’s holdings in Guardant Health were worth $22,562,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $233,000. Teachers Retirement System of The State of Kentucky bought a new stake in Guardant Health in the fourth quarter worth $3,868,000. Eventide Asset Management LLC boosted its holdings in Guardant Health by 8.3% in the fourth quarter. Eventide Asset Management LLC now owns 3,888,146 shares of the company’s stock worth $105,174,000 after acquiring an additional 298,616 shares in the last quarter. Cadian Capital Management LP bought a new stake in Guardant Health in the fourth quarter worth $19,206,000. Finally, Capital International Investors boosted its holdings in Guardant Health by 36.7% in the fourth quarter. Capital International Investors now owns 4,001,803 shares of the company’s stock worth $108,249,000 after acquiring an additional 1,074,452 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Up 1.3 %

Guardant Health stock opened at $29.48 on Wednesday. The stock has a market cap of $3.61 billion, a PE ratio of -7.52 and a beta of 1.14. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $41.06. The stock has a fifty day moving average of $24.21 and a 200 day moving average of $22.90.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.94) EPS for the quarter, meeting analysts’ consensus estimates of ($0.94). The company had revenue of $168.49 million during the quarter, compared to analysts’ expectations of $150.51 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. As a group, sell-side analysts predict that Guardant Health, Inc. will post -3.31 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on GH shares. Canaccord Genuity Group boosted their target price on Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. Jefferies Financial Group started coverage on Guardant Health in a report on Monday, June 3rd. They issued a “buy” rating and a $32.00 target price on the stock. The Goldman Sachs Group dropped their target price on Guardant Health from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, April 15th. Stephens restated an “overweight” rating and issued a $44.00 price target on shares of Guardant Health in a research note on Friday, May 24th. Finally, Craig Hallum assumed coverage on Guardant Health in a research note on Wednesday, April 24th. They issued a “buy” rating and a $28.00 price target for the company. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $36.91.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.